Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Few areas of pharmaceutical manufacturing have attracted as much investment in recent years as high-potency containment. The expansion of oncology…
Partner Content
-
-
How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies…
-
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
When a warning letter from the U.S. Food and Drug Administration (FDA) lands on a quality leader's desk, the instinct…
-
What drives time-to-randomization in oncology trials?
In the United States, an estimated 2,041,910 new cases of cancer were diagnosed in 2025, with 618,120 people dying from…
-
Develop site-centric protocols to optimize enrollment and maximize performance
In an attempt to meet regulatory expectations, clinical trials are challenged by highly complex protocol design. But these study plans…
-
Remedying the paper trail: Manufacturing a digital route to compliance
Regulatory investigators’ remit extends beyond routine standard operating procedure (SOP) reviews; they watch how operators work, how equipment is qualified,…
-
Why CMC readiness is becoming central to biopharma licensing deals
Biopharma licensing is becoming more operational. Buyers and partners still begin with the quality of the science, but they also…
-
Asia’s clinical research revolution: Why the world’s innovation centre is shifting east
The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials,…
-
Reaching maturity: A roadmap for Quality Excellence amid regulatory transformation
The regulatory landscape across life sciences has faced unprecedented shifts over the past year. Simultaneous realignments of FDA, EU, and…
-
Why your manufacturing floor is your greatest compliance risk – and opportunity
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to…